Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug

Grace Therapeutics Inc. (NASDAQ:GRCE) shares are down during Friday's premarket session following a regulatory update regarding its New Drug Application (NDA) for GTx-104.